Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy
There is a critical unmet need for scalable, accessible and objective diagnostic tests for stratification in dementia. Biofluid Raman spectroscopy (RS) due to its simplicity, holistic and label-free nature, is a powerful approach that has the potential to offer differential diagnosis across dementia types including Alzheimer’s disease (AD). RS is a laser-based optical method that can rapidly provide chemically rich information (‘spectral biomarkers’) from biofluids but its utility for AD diagnosis has not been established in a ‘real-world’ context, specifically from a clinically heterogenous cohort of patients. We carried out RS measurements on cerebrospinal fluid (CSF) samples of patients from a mixed clinical cohort (N = 143). All patients reported cognitive complaints and were clinically diagnosed over 2 years with conditions including AD and other neurodegenerative diseases, as well as developmental and long-term chronic conditions. Machine-learning algorithms were trained, optimised and evaluated on Raman spectra to classify AD from non-AD. AD was classified with 93% accuracy for patients in the testing set. Time from sample to classification was < 1 h. Spectral biomarkers explaining AD classification were identified and primarily assigned to protein-derived aromatic amino acids, representing a difference in proteome signature between AD and non-AD groups. Signals from a subset of spectral biomarkers directly correlated with pathological CSF biomarker concentrations including amyloid-β 42, phosphorylated-tau 181, and total tau. This pre-clinical study is a first step towards realising the real-world application of RS for dementia diagnosis. Compared to current and emerging methods, RS does not require sophisticated instrumentation or specialised labs. It is reagentless and simple, offering unprecedented rapidity, scalability, accessibility for dementia diagnosis.
Devitt, George
088c46c0-9dcf-4c83-acfd-16c6c9d0ca88
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Perunthadambil Kadalayil, Latha
e620b801-844a-45d9-acaf-e0a58acd7cf2
Hanrahan, Niall
df8a0edc-a5bd-4979-aa6f-0ea1bff159c3
Prosser, Angus
de1efee5-67f5-478e-8cfa-12a8e78a68e5
Ghosh, Boyd
f8e37115-eb7a-427b-ad2a-d1d5acb26552
Mudher, Amritpal
ce0ccb35-ac49-4b6c-92b4-8dd5e78ac119
Kipps, Chris
e43be016-2dc2-45e6-9a02-ab2a0e0208d5
Mahajan, Sumeet
b131f40a-479e-4432-b662-19d60d4069e9
21 October 2025
Devitt, George
088c46c0-9dcf-4c83-acfd-16c6c9d0ca88
Michopoulou, Sofia
f21ba2a3-f5d3-4998-801f-1ae72ff5d92c
Perunthadambil Kadalayil, Latha
e620b801-844a-45d9-acaf-e0a58acd7cf2
Hanrahan, Niall
df8a0edc-a5bd-4979-aa6f-0ea1bff159c3
Prosser, Angus
de1efee5-67f5-478e-8cfa-12a8e78a68e5
Ghosh, Boyd
f8e37115-eb7a-427b-ad2a-d1d5acb26552
Mudher, Amritpal
ce0ccb35-ac49-4b6c-92b4-8dd5e78ac119
Kipps, Chris
e43be016-2dc2-45e6-9a02-ab2a0e0208d5
Mahajan, Sumeet
b131f40a-479e-4432-b662-19d60d4069e9
Devitt, George, Michopoulou, Sofia, Perunthadambil Kadalayil, Latha, Hanrahan, Niall, Prosser, Angus, Ghosh, Boyd, Mudher, Amritpal, Kipps, Chris and Mahajan, Sumeet
(2025)
Classification of Alzheimer’s disease in a mixed clinical cohort using biofluid Raman spectroscopy.
Alzheimer's Research & Therapy, 17 (1), [228].
(doi:10.1186/s13195-025-01879-4).
Abstract
There is a critical unmet need for scalable, accessible and objective diagnostic tests for stratification in dementia. Biofluid Raman spectroscopy (RS) due to its simplicity, holistic and label-free nature, is a powerful approach that has the potential to offer differential diagnosis across dementia types including Alzheimer’s disease (AD). RS is a laser-based optical method that can rapidly provide chemically rich information (‘spectral biomarkers’) from biofluids but its utility for AD diagnosis has not been established in a ‘real-world’ context, specifically from a clinically heterogenous cohort of patients. We carried out RS measurements on cerebrospinal fluid (CSF) samples of patients from a mixed clinical cohort (N = 143). All patients reported cognitive complaints and were clinically diagnosed over 2 years with conditions including AD and other neurodegenerative diseases, as well as developmental and long-term chronic conditions. Machine-learning algorithms were trained, optimised and evaluated on Raman spectra to classify AD from non-AD. AD was classified with 93% accuracy for patients in the testing set. Time from sample to classification was < 1 h. Spectral biomarkers explaining AD classification were identified and primarily assigned to protein-derived aromatic amino acids, representing a difference in proteome signature between AD and non-AD groups. Signals from a subset of spectral biomarkers directly correlated with pathological CSF biomarker concentrations including amyloid-β 42, phosphorylated-tau 181, and total tau. This pre-clinical study is a first step towards realising the real-world application of RS for dementia diagnosis. Compared to current and emerging methods, RS does not require sophisticated instrumentation or specialised labs. It is reagentless and simple, offering unprecedented rapidity, scalability, accessibility for dementia diagnosis.
Text
s13195-025-01879-4
- Version of Record
More information
Accepted/In Press date: 30 September 2025
Published date: 21 October 2025
Identifiers
Local EPrints ID: 505971
URI: http://eprints.soton.ac.uk/id/eprint/505971
ISSN: 1758-9193
PURE UUID: cb0a2598-f396-4dab-8ff2-729320af7941
Catalogue record
Date deposited: 24 Oct 2025 16:46
Last modified: 05 Nov 2025 18:13
Export record
Altmetrics
Contributors
Author:
Sofia Michopoulou
Author:
Niall Hanrahan
Author:
Boyd Ghosh
Author:
Chris Kipps
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics